DeepMed Research

Hutchmed Limited

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: $2.9B

Website

Clinical Trials

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: HMPL-760

First Posted Date: 2022-01-13

Last Posted Date: 2025-04-09

Lead Sponsor: Hutchmed

Target Recruit Count: 89

Registration Number: NCT05190068

Locations: 🇨🇳
Beijing Chao-Yang Hospital, Capital Medical University, Beijing, Beijing, China
🇨🇳
The First Affiliated Hospital of Xiamen University, Xiameng, Fujian, China
🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

and more 19 locations

HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL

Phase 1

Withdrawn

Conditions: Waldenstrom Macroglobulinemia
Follicular Lymphoma
MZL
CLL/SLL
NHL
Lymphoplasmacytic Lymphoma
Richter Syndrome
MCL
DLBCL

Interventions: Drug: HMPL-760

First Posted Date: 2022-01-04

Last Posted Date: 2023-02-21

Lead Sponsor: Hutchmed

Registration Number: NCT05176691

Locations: 🇵🇱
MICS Centrum Medyczne Torun, Toruń, Poland
🇮🇱
Rabin Medical Center-Beilinson Campus, Petach-Tikva, Israel
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

and more 32 locations

A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Osteosarcoma
Ewing Sarcoma
Rhabdomyosarcoma
Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)
Lymphoma

Interventions: Drug: Surufatinib in combination with Gemcitabine

First Posted Date: 2021-10-26

Last Posted Date: 2024-06-07

Lead Sponsor: Hutchmed

Target Recruit Count: 13

Registration Number: NCT05093322

Locations: 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸
Childrens Hospital Orange County, Orange, California, United States
🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States

and more 8 locations

Open-label Study of Surufatinib in Japanese Patients

Phase 1

Active, not recruiting

Conditions: Neuroendocrine Tumors
Non-hematologic Malignancy

Interventions: Drug: Surufatinib

First Posted Date: 2021-10-14

Last Posted Date: 2024-05-24

Lead Sponsor: Hutchmed

Target Recruit Count: 36

Registration Number: NCT05077384

Locations: 🇯🇵
Kagawa University Hospital, Kagawa, Japan
🇯🇵
Tohoku University Hospital, Sendai, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 9 locations

A Study of HMPL-295S1 in Patients With Advanced Malignant Solid Tumors

Phase 1

Completed

Conditions: Advanced Malignant Solid Tumors

Interventions: Drug: HMPL-295S1 with dose escalation stage of 5mg up to 200mg, then expansion stage with recommended dose of therapeutic cycle of 28 days .

First Posted Date: 2021-06-01

Last Posted Date: 2024-10-11

Lead Sponsor: Hutchmed

Target Recruit Count: 47

Registration Number: NCT04908046

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Expanded Access Program of Surufatinib

Conditions: Neuroendocrine Tumors

First Posted Date: 2021-03-24

Last Posted Date: 2024-04-12

Lead Sponsor: Hutchmed

Registration Number: NCT04814732

Locations: 🇺🇸
Rocky Mountain Cancer Center, Denver, Colorado, United States
🇺🇸
Mercy Medical Center, Medical Oncology & Hematology, Baltimore, Maryland, United States
🇺🇸
Avera Cancer Institute, Sioux Falls, South Dakota, United States

and more 8 locations

A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations

Phase 1

Active, not recruiting

Conditions: Isocitrate Dehydrogenase Gene Mutation

Interventions: Drug: HMPL-306

First Posted Date: 2021-02-21

Last Posted Date: 2024-10-23

Lead Sponsor: Hutchmed

Target Recruit Count: 90

Registration Number: NCT04762602

Locations: 🇪🇸
Hospital de la Santa creu i Sant Pau, Barcelona, Spain
🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Spain
🇪🇸
Hospital Universitari Vall d'Hebron, Barcelona, Spain

and more 8 locations

A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH

Phase 1

Terminated

Conditions: Isocitrate Dehydrogenase Gene Mutation

Interventions: Drug: HMPL-306

First Posted Date: 2021-02-21

Last Posted Date: 2025-04-10

Lead Sponsor: Hutchmed

Target Recruit Count: 46

Registration Number: NCT04764474

Locations: 🇺🇸
University of California Irvine Medical Center (UCIMC) - Chao Family Comprehensive Cancer Center, Orange, California, United States
🇪🇸
Institut Catala d'Oncologia de l'Hospitalet de Llobregat - Hospital Duran i Reynals, Barcelona, Spain
🇪🇸
Hospital Universitario de Salamanca, Salamanca, Spain

and more 12 locations

Open-Label Surufatinib in European Patients with NET

Phase 2

Completed

Conditions: Neuroendocrine Tumours
Neuroendocrine Tumour of the Lung
Small Intestinal NET

Interventions: Drug: Surufatinib

First Posted Date: 2020-10-08

Last Posted Date: 2025-03-20

Lead Sponsor: Hutchmed

Target Recruit Count: 78

Registration Number: NCT04579679

Locations: 🇺🇸
Houston Methodist, Hosuton, Texas, United States
🇫🇷
CHU Bordeaux, Pessac, France
🇫🇷
Institut Gustave Roussy, Villejuif, France

and more 20 locations

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Phase 1

Terminated

Conditions: Neuroendocrine Tumors
Small Cell Lung Cancer
Metastatic Solid Tumor
Colorectal Cancer
Soft Tissue Sarcoma
Anaplastic Thyroid Cancer
Gastric Cancer

Interventions: Drug: Surufatinib and Tislelizumab _ Part 1
Drug: Surufatinib and Tislelizumab _ Part 2

First Posted Date: 2020-10-08

Last Posted Date: 2025-05-08

Lead Sponsor: Hutchmed

Target Recruit Count: 87

Registration Number: NCT04579757

Locations: 🇺🇸
Arizona Oncology Associated, PC-HOPE, Tucson, Arizona, United States
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
Johns Hopkins University - Sibley Memorial Hospital, Washington, District of Columbia, United States

and more 14 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy